Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon's comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.

1 Dec 2010

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has begun Phase 1/2a clinical testing with its lead compound, Glymera(PB1023), in patients with Type 2 diabetes.

1 Dec 2010

FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA

Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).

30 Nov 2010

Are vitamin D and calcium supplements needed?

The IOM raised the recommended dietary allowance of vitamin D from the amount cited in their last report, released 13 years ago. It said that although 600 international units (IUs) of vitamin D or more each day is sufficient to maintain bone health in majority. But those aged 71 and older may need as much as 800 IUs daily, the IOM experts say. However 1997 recommendations advised 400 IUs per day for people aged 51 to 70 and 600 IUs per day for those over 70.

30 Nov 2010

Largest remote health monitoring project in the world launched in China

Canada-based IDEAL LIFE and China's Shandong NovaTech Biological Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer and medical products distribution network in China, announced the launch of the largest remote health monitoring project in the world, bringing wireless, remote health monitoring to the People's Republic of China.

30 Nov 2010

Super-sized World conference to address national health crisis of obesity

A conference at the New York Academy of Sciences on December 9 will convene leading obesity researchers to explore the latest science and policy initiatives addressing the global and national health crisis of obesity.

30 Nov 2010

Methodist to develop national training center for treatment of cardiovascular disease

The Methodist DeBakey Heart & Vascular Center recently received a generous gift to develop a national training center for surgical and interventional treatments for cardiovascular disease, the number one killer of Americans. The benefactor wishes to remain anonymous.

30 Nov 2010

miRagen and t2cure enter licensing agreement for microRNA 92 technology

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced today that they have entered into a licensing agreement

30 Nov 2010

Dongsheng enters agreement to acquire micro-emulsion alprostadil injection from Wan'Te

Dongsheng Pharmaceutical International Co., Ltd. announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock.

30 Nov 2010

People with OSA are prone to develop atherosclerosis: Study

People with obstructive sleep apnea (OSA), a sleep disorder associated with obesity, have more non-calcified or "bad" plaque in their coronary arteries, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2010

Study confirms difference in coronary artery disease pathways among Caucasians, African Americans

In a study being presented today at the annual meeting of the Radiological Society of North America (RSNA), researchers say they may have an explanation as to why African Americans, despite having lower amounts of coronary artery calcification, are at increased risk for heart attacks and other cardiovascular events compared with Caucasians.

30 Nov 2010

MEDRAD launches VirtualCARE solution for Intego PET Infusion System

MEDRAD, Inc. a business of Bayer HealthCare, today announces the U.S. launch of VirtualCARE®, for the MEDRAD Intego™ PET Infusion System. VirtualCARE is a technology platform that allows MEDRAD to remotely support maintenance and system updates securely over the internet.

29 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.

29 Nov 2010

Researchers identify effects of endurance running

Using a mobile MRI unit, researchers followed runners for two months along a 4,500-kilometer course to study how their bodies responded to the high-stress conditions of an ultra-long-distance race, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2010

New strategy to prevent memory deficits in mouse model with AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) in San Francisco have discovered a new strategy to prevent memory deficits in a mouse model of Alzheimer's disease (AD).

28 Nov 2010

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

Segasist Technologies, a Canadian software company developing contouring productivity tools for medical imaging, has today announced the receipt of funding from The Health Technology Exchange (HTX) towards support of clinical validation of its software, to be conducted at the Lawson Health Research Institute and London Health Sciences Centre (London, Ontario). Experts from Sunnybrook Research Institute and Sunnybrook Health Sciences Centre will also participate in the validation process by providing input in the form of gold standard contours.

26 Nov 2010

New WHO report highlights second-hand smoke danger

A report, a first of its kind, that assessed all deaths related to tobacco showed that secondhand smoke sickens millions and kills more than 600,000 people worldwide each year, including more than 165,000 children under 5.

25 Nov 2010

UMDNJ researchers develop comprehensive strategy for recovery from smoking addiction

Researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ), following 10 years of studying tobacco use among smokers with mental illness, have developed a comprehensive strategy for recovery from smoking addiction that could serve as a nationwide model.

25 Nov 2010

Genzyme meets FDA consent decree by ending fill/finish activities in Allston plant

Genzyme Corporation announced today that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree.

25 Nov 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA

Are vitamin D and calcium supplements needed?

Largest remote health monitoring project in the world launched in China

Super-sized World conference to address national health crisis of obesity

Methodist to develop national training center for treatment of cardiovascular disease

miRagen and t2cure enter licensing agreement for microRNA 92 technology

Dongsheng enters agreement to acquire micro-emulsion alprostadil injection from Wan'Te

People with OSA are prone to develop atherosclerosis: Study

Study confirms difference in coronary artery disease pathways among Caucasians, African Americans

MEDRAD launches VirtualCARE solution for Intego PET Infusion System

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Researchers identify effects of endurance running

New strategy to prevent memory deficits in mouse model with AD

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

New WHO report highlights second-hand smoke danger

UMDNJ researchers develop comprehensive strategy for recovery from smoking addiction

Genzyme meets FDA consent decree by ending fill/finish activities in Allston plant

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in